THDB(SH:600867) Zhong Guo Zheng Quan Bao·2025-10-24 13:42Core Viewpoint - Tonghua Dongbao has received approval from the Indonesian Food and Drug Authority for the registration of its Aspart Insulin Injection, marking a significant step in the company's international expansion and addressing the growing diabetes treatment needs in Indonesia [1][2]. Group 1: Product Approval and Market Expansion - The approval of Aspart Insulin Injection allows Tonghua Dongbao to sell this product in Indonesia, a major market, following its previous success in Myanmar [1]. - The company has been accelerating its internationalization efforts, achieving important milestones in markets such as Uzbekistan, Nicaragua, Myanmar, and Indonesia this year [2]. - The approval signifies a shift from a focus on raw human insulin to a more diverse product portfolio, including both raw materials and formulations, establishing a robust overseas product system [2]. Group 2: Market Demand and Patient Needs - Indonesia has a rising demand for medical services, with the International Diabetes Federation reporting that the number of diabetes patients aged 20-79 is expected to reach 20.43 million in 2024, with a prevalence rate of 11.0% [1]. - There is a significant gap in diabetes diagnosis and treatment in Indonesia, with 73.2% of diabetes patients undiagnosed, highlighting the urgent need for effective treatment options [1]. Group 3: Future Strategy and Goals - Tonghua Dongbao plans to leverage its production advantages to provide safe, effective, and affordable medical products for endocrine patients globally, aiming to expand its overseas sales [3]. - The company intends to continue registering its insulin products in more countries, starting from Indonesia and Myanmar, and is also focused on advancing the regulatory processes for its products in the U.S. and Europe [3].